Kornimate/medical-research-clean huggingface dataset:
pain education to improve cancer pain management patients

Conditions: Pain; Inpatient; Cancer

Summary: cancer pain is one of the problems of treating cancer pain. although, there is a who analgesic ladder to improve this problem, it is still inadequate pain control. pain does not affect only physical but also emotional and quality of life. from review literatures we found that patients' knowledge about cancer pain management is inaccurate; for example, fear to use opioid, try to patience of pain, concerning only cancer treatments, which can cause of unfavorable pain management outcome. therefore, we will conduct the rct of using pain education by video comparing to conventional face to face pain education by nurse in hospitalized cancer pain patients.we will use 25 mcqs examination for testing pre-post intervention to test level of understanding of patients. the measurements are nrs, thaihads and fact-g at the first and last day of study. we expect that nrs should improve more than 50% at the seven day of study.

protocol randomized controlled trial study sample size is 70 patients divided to 2 groups (35 for video group and 35 for conventional face to face group) inclusion criteria 1. patients' age 18-70 years old 2. moderate to severe cancer pain 3. ecog(eastern cooperative oncology group) performance status \<= 3 4. patients can write and read thai language exclusion criteria 1.clinical unstability 2.confusion and delirium 3.bed ridden 4.psychotic problem we will randomly allocate patients by using computer program nquery advice 6.0. after patients sign inform consent we will record baseline characteristics, assess baseline numerical rating scale (nrs), emotional status (thaihads), quality of life status (fact-g). all patients will do the 25 mcqs test within 30 minutes before intervention. video group will watch video 10 minutes and conventional group will receive pain education from trained nurse in the same period. the knowledge includes cancer pain definition, cancer pain management, pain assessment and role of patients in cancer pain management. after finishing intervention patients will the same 25 mcqs test (30 minutes) and patients can ask questions to the trained nurse. all patients will be educated to record pain diary everyday for seven days. all patients will receive standard pain management from the physicians. at the day seven we will assess nrs, thaihads and fact-g and finish the study.

Eligibility criteria:
inclusion criteria: * moderate to severe pain (nrs\>4) cancer pain * ecog (eastern cooperative oncology group) performance status \<=3 * can read, listen, write thai language exclusion criteria: * clinical instability * confusion and delirium * bed ridden * psychotic problem
discovery of novel biomarkers that will lead to the early detection of alzheimer's disease

Conditions: Mild Cognitive Impairment; Alzheimer Disease

Summary: this study will perform a targeted metabolic analysis in blood and urine samples from subjects attending the baylor at\&t memory center. the aim is to identify novel biomarkers that can distinguish normal aging subjects with no cognitive impairment from those with mild, moderate or severe cognitive impairment associated with alzheimer's disease. subjects will also be screened for b-vitamin deficiencies that may correlate with other metabolic biomarkers and alzheimer's disease.

all subjects will be clinically assessed using standard measures of clinical care. cognitive function will be assessed by the montreal cognitive assessment (moca). disease severity will be assessed by the clinical dementia rating scale (cdr). social function will be assessed by the functional activities questionnaire (faq). based on clinical assessment, subjects will be classified into one of the following groups. 1. normal (spouse or caregiver) 2. mild cognitive impairment 3. alzheimer's disease a. mild b. moderate c. severe the investigators plan to enroll 60 subjects in each group from 1 and 2; 40 subjects in each of the groups 3a and 3b and 20 subjects in group 3c.

Eligibility criteria:
inclusion criteria: a. both males and females b. patients at least 40-years of age c. mild cognitive impairment d. alzheimer 's disease 1. mild 2. moderate 3. severe exclusion criteria: a. no recent major surgery within the last 6 months b. free of any malignant disease c. no chronic renal disease d. no other major neurodegenerative disorders (i.e. parkinson's disease, multiple sclerosis)
single and multiple dose study in japanese

Conditions: Gout

Summary: this study will explore the safety, tolerability, and serum uric acid lowering effect of lesinurad in healthy japanese males to allow comparison with the western population.

while there is extensive clinical experience with lesinurad in the western population, it is recognized that both intrinsic and extrinsic factors may impact the pk, pd, safety, and dose response in different ethnic populations. the purpose of this study is to explore the safety, tolerability, pharmacokinetic (pk), and pharmacodynamic (pd) of single and multiple doses of lesinurad in healthy japanese males, and to allow comparison of these parameters with the western population.

Eligibility criteria:
inclusion criteria: * able to understand the study procedures, the risks involved and willing to provide written informed consent before the first study related activity. * healthy adult subjects born in japan * all laboratory parameters should be within normal limits or considered not clinically significant by the investigator. * screening serum uric acid level \>= 4.5 mg/dl. * subjects must be free of any clinically significant disease that requires a physician's care and/or would interfere with study evaluations or procedures. * subject does not have clinically relevant abnormalities in blood pressure, heart rate, body temperature, and respiratory rate, as per the investigator's judgment. exclusion criteria: * positive serology to human immunodeficiency virus (hiv-1 and hiv-2). * positive test for active hepatitis b or hepatitis c infection. * history of kidney stones. * undergone major surgery within 3 months of day 1. * subject has received the last dose of an investigational drug (or treatment with a medical device) within 30 days or 5 half-lives (whichever is longer) of the investigational drug prior to day 1 or are currently participating in another study of an investigational drug (or medical device). * prior exposure to lesinurad (rdea594) or rdea806.
use of hair to diagnose breast cancer

Conditions: Breast Neoplasms

Summary: study ft3.6k-2006 is a single centre (the mater hospital, sydney), blinded trial of a diagnostic test for breast cancer, with outcomes compared to the gold standard of screening mammogram followed by biopsy where required. this study aims to perform x-ray diffraction analysis of coded hair samples from women with a documented breast health status, to validate the findings of james et al (nature 398: 33-4, 1999; int j cancer 114: 969-72, 2005) who showed that the presence of breast cancer could be detected using synchrotron-derived x-ray diffraction of human hair (scalp or pubic). the aim is also to characterise the sensitivity and specificity of the hair test in detecting breast cancer in a screening setting, and to determine the significance of a positive hair test and a negative mammogram.

the test has the potential to improve the diagnostic (and consequently therapeutic) paradigm for breast cancer. women attending a radiology clinic in the mater hospital, sydney, for a mammogram will be invited to participate in the study. a few hairs will be cut from their head or pubic region, put into a coded container and sent to the sponsor for analysis by synchrotron-x-ray diffraction. although an imperfect standard for a variety of reasons, mammography is the standard screening assay, and confirmation of the pathology of the lesions found by mammography is carried out by biopsy. this will be the standard to which the hair test results will be compared. a negative mammogram will confirm a negative hair test, but a negative mammogram combined with a positive hair diffraction test will need a different approach. in the event of a positive hair test and a negative second read of the mammogram, the patient will be contacted by the referring practitioner. patients in this category will be offered a breast mri. a negative breast mri under these circumstances will be classified as a true negative.

Eligibility criteria:
inclusion criteria: * adult women (aged \>20) who are undergoing mammography at the mater hospital, sydney, and * who are willing and able to provide informed consent; and * who have usable scalp and/or pubic hair exclusion criteria: * women who have dyed or permed their scalp hair within the previous 6 weeks and whose pubic hair is unavailable; * women with a history of breast cancer ever or other cancers (excluding non-melanoma skin cancer and cin \[cervical intra-epithelial neoplasia\]) within 5 years.

Keywords: breast cancer hair fibre synchrotron x-ray diffraction
impact of maternal bmi on plasma levels of oxytocin during labor augmentation

Conditions: Maternal Obesity During Childbirth; Labor; Arrested Active Phase

Summary: the aim of this study is to examine the associations between maternal bmi and levels of oxytocin in maternal plasma during augmentation with oxytocin during first stage of labor in term pregnancy.

a translational prospective experimental study in the delivery ward in linköping. the study population will include women in two bmi groups (underweight/normal weight and overweight/obese) during first stage of labor with singleton full term pregnancy and cephalic presentation.the bmi is calculated from weight and height registered at the first antenatal visit around week 8-12. at the delivery ward, if the women are in need of labor augmentation with oxytocin infusion, a peripheral venous catheter will be placed in the contralateral arm from the arm where oxytocin will be administrated. the oxytocin infusion will be prepared to a concentration of 10 mu/ml and will be given according to a standardized protocol or to an infusion level giving maximum of 5 uterine contractions per 10 minutes. blood samples for measuring plasma levels of oxytocin will be taken prior to start and before every increase in the rate of oxytocin infusion. the blood samples will be collected through the first stage of labor.

Eligibility criteria:
inclusion criteria: full-term pregnancy (from gestational week 37+0), singel pregnancy, vertex presentation, knowledge in the swedish language, 18 years and older, known bmi, need of labor augmentation with oxytocin infusion during opening stage. exclusion criteria: not participating in other studies at the delivery ward

Keywords: labor obesity oxytocin
study to assess the efficacy and safety of lanreotide autogel® in chinese participants with gep-nets

Conditions: Gastroenteropancreatic Neuroendocrine Tumor

Summary: this study will be conducted to support the registration of the lanreotide autogel 120 mg formulation in china for the treatment of gep-nets and treatment of clinical symptoms of nets. the study will include a screening period of up to 4 weeks followed by a 48-week intervention period. after completion of the main study period, five participants will continue in a self/partner injection cohort with lanreotide autogel 120 mg every 28 days for 24 weeks.


Eligibility criteria:
inclusion criteria: * capable of giving signed informed consent * male or female of 18 years of age or older when informed consent is obtained * has a histologically proven grade 1 or 2 gep-net according to who (world health organisation) classification * has an unresectable metastatic or locally advanced net. * has an eastern cooperative oncology group (ecog) performance status lower or equal to 2. exclusion criteria: * participants with poorly differentiated gastroenteropancreatic neuroendocrine carcinoma (gep-nec), high-grade gep-nec and goblet cell carcinoid. * has been treated with octreotide acetate long-acting release or lanreotide acetate autogel formulation within 8 weeks prior to screening tests or lanreotide pr 40 mg within 4 weeks prior to screening tests. * has been treated with subcutaneous or intravenous octreotide acetate within 1 week prior to screening tests. * has been treated with mammalian target of rapamycin (mtor) inhibitors or multi-target tyrosine kinase (mtk) inhibitors within 4 weeks prior to screening tests.
effectiveness of nasal-alar elevator combined with taping vs. taping alone on improving the nose esthetics and maxillary arch dimensions in infants with unilateral complete cleft lip and palate

Conditions: Cleft Lip and Palate

Summary: this randomized trial is designed to assess the effectiveness of nasal elevator as a presurgical infant orthopedics on improvement of nose esthetics vs taping alone.


Eligibility criteria:
inclusion criteria: * infants with age range from 1-30 days. * unilateral complete cleft lip and alveolus. * medically free subjects. * both males and females. * cleft gap more than 10 mm. exclusion criteria: * patients older than 30 days. * syndromic patients with other defects in addition to cleft lip and palate. * patients with bilateral cleft lip and palate. * incomplete cleft lip. * patient with previous surgical lip repair or adhesion. * patients with previous presurgical infant orthopedic treatment. * medically compromised patients. * cleft gap distance less than 10mm
physical activity component of the greek interventional geriatric study to prevent cognitive impairment and disability (ginger)

Conditions: People With Subjective Cognitive Impairement (SCI)

Summary: the greek interventional geriatric study to prevent cognitive impairment and disability (ginger) is a six-month multimodal, multicenter study aimed at people with subjective cognitive impairement (sci). one of the ginger's interventional components is the physcial activity (pa) component, coordinated by the university of patras. this pa component's scope is to determine whether an enhanced individualized physical exercise intervention programme can improve cognitive changes, physical function, quality of life and wellbeing in people with subjective cognitive decline.


Eligibility criteria:
inclusion criteria include people with: * subjective cognitive decline confirmed from the subjctive cognitive decline questionnaire (scd - q score \>7) * absence of objective cognitive imparement as confirmed from cognitive assessment tests (i.e. moca, trail a \& b, stroop, rcft, fas. ) exclusion criteri include people with: * mild cognitive impairement (mci) or dementia * chronic psychiatric or neurological disorders affecting cognition (i.e. bipolar disorder, schizophrenia, ms, tbi, parkinson's disease etc.) * unstable pathological diseases (i.e. uncontrolled hypothyrodism, athythmias, uncontrolled hypertension, high blood pressure at rest etc.) * recent (\<6 month) surgery, which restrics active participation in exercise/physical activity * inadequate knowledge of greek
efficacy and safety of spd465 in adults with adhd

Conditions: Attention Deficit Disorder With Hyperactivity

Summary: the purpose of this study is to assess the safety and effectiveness of spd465 compared to placebo (a capsule with no medication in it) in the treatment of adhd. the study will also look at how spd465 affects sleep and how the participants perceive their quality of life.


Eligibility criteria:
inclusion criteria: * primary diagnosis of adhd * baseline adhd-rs-iv score \>= 24 * non-pregnant females of childbearing potential must comply with contraceptive restrictions exclusion criteria: * significantly underweight or morbidly obese * comorbid psychiatric diagnosis with significant symptoms such as axis ii disorders or severe axis i disorders * history of seizure, tic disorder, or a current diagnosis and/or family history of tourette's disorder
phase 2b extension study of ataluren (ptc124) in duchenne/becker muscular dystrophy (dmd/bmd)

Conditions: Duchenne Muscular Dystrophy; Becker Muscular Dystrophy

Summary: duchenne/becker muscular dystrophy (dmd/bmd) is a genetic disorder that develops in boys. it is caused by a mutation in the gene for dystrophin, a protein that is important for maintaining normal muscle structure and function. loss of dystrophin causes muscle fragility that leads to weakness and loss of walking ability during childhood and teenage years. a specific type of mutation, called a nonsense (premature stop codon) mutation is the cause of dmd/bmd in approximately 10-15% of boys with the disease. ataluren (ptc124) is an orally delivered, investigational drug that has the potential to overcome the effects of the nonsense mutation. this study is a phase 2b extension trial that will evaluate the long-term safety of ataluren (ptc124) in boys with nonsense mutation dmd/bmd, as determined by adverse events and laboratory abnormalities. the study will also assess changes in walking, muscle function, and other important clinical and laboratory measures.

this is a phase 2b, international, multicenter, open-label extension study for participants who successfully completed blinded study drug in study 007. this extension study will evaluate the long-term administration of ataluren administered 3 times per day (tid) at morning, midday, and evening doses of 20, 20, and 40 milligrams/kilogram (mg/kg), respectively, in participants with nonsense mutation duchenne/becker muscular dystrophy (nmdbmd).

Eligibility criteria:
inclusion criteria: * completion of blinded study drug treatment in the previous phase 2b study (ptc124-gd-007-dmd). * ability to provide written informed consent (parental/guardian consent if applicable)/assent (if less than \[\<\]18 years of age). * in participants who are sexually active, willingness to abstain from sexual intercourse or employ a barrier or medical method of contraception during ptc124 administration and the 6-week follow up period. * willingness and ability to comply with scheduled visits, drug administration plan, study procedures, laboratory tests, and study restrictions. exclusion criteria: * known hypersensitivity to any of the ingredients or excipients of the study drug (litesse® ultratm \[refined polydextrose\], polyethylene glycol 3350, lutrol® micro f127 \[poloxamer 407\], mannitol 25c, crospovidone xl10, hydroxyethyl cellulose, vanilla, cab-o-sil® m5p \[colloidal silica\], magnesium stearate). * ongoing participation in any other therapeutic clinical trial. * prior or ongoing medical condition (for example, concomitant illness, psychiatric condition, behavioral disorder, alcoholism, drug abuse), medical history, physical findings, ecg findings, or laboratory abnormality that, in the investigator's opinion, could adversely affect the safety of the subject, makes it unlikely that the course of treatment or follow up would be completed, or could impair the assessment of study results.

Keywords: duchenne muscular dystrophy becker muscular dystrophy nonsense mutation premature stop codon dmd bmd ataluren ptc124
caloric restriction before surgery in treating patients with endometrial, prostate, or breast cancer

Conditions: Breast Carcinoma; Endometrial Carcinoma; Prostate Carcinosarcoma

Summary: the purpose of this trial is to determine that sort term calorie restriction will affect tumor biology in biopsy proven breast, endometrial or prostate cancers, which will positively impact biomarkers including mir-21, an onco-mir known to impact cancer outcomes.

primary objectives: 1) investigate if caloric restriction will change serum micro ribonucleic acid (rna) 21 (mir-21) expression in patients with prostate, endometrial or breast cancer. secondary objectives: 1. investigate measurable changes induced by caloric restriction on both patient (host) and tumor characteristics from caloric restriction. 2. investigate the adherence of the patient to the diet. 4) weight, height, and body composition will be assessed via bodymetrix. bodymetrix uses ultrasound technology to measure subcutaneous fat. 5) patients will have psycho-social evaluation using the functional assessment of cancer therapy-prostate (fact-p) test (prostate cancer), fact-breast (b) test (breast cancer), or the fact-endometrial cancer (en) test (endometrial cancer) and the patient reported outcomes measurement information system (promis) cancer fatigue short form at baseline, midway through diet, and at the conclusion of the diet. 6) patient's nutritional status (mini nutritional assessment \[mna\] form) will be assessed, and their caloric needs will be calculated. 7) local recurrence, progression free survival, distant metastases and overall survival will be assessed.

Eligibility criteria:
inclusion criteria: 1. histological documentation of cancer of the endometrium, prostate or breast. 2. candidate for definitive cancer surgery as determined by treating physician 3. the ability for the definitive cancer surgery to be scheduled within 4-12 weeks post initiation of dietary intervention as determined by the enrolling physician (not from diagnosis - but from start of diet). 4. no other malignancy within the past 6 months unless it was a non-melanomatous skin lesion 5. bmi ≥21 6. ecog performance status of 2 or less 7. patient must not be on anti-retrovirals since they may alter patient metabolism exclusion criteria: 1. patient is not a candidate for definitive cancer surgery 2. definitive cancer surgery can not be performed within 4-12 weeks post study enrollment as determined by the enrolling physician. 3. body mass index \< 21 4. another malignancy within the past 6 months that was not a non-melanomatous skin lesion 5. ecog performance status \>2 6. patient on anti-retrovirals since they may alter patient metabolism
effectiveness of video messaging about diet, exercise and weight gain in pregnancy in regional and national samples

Conditions: Pregnancy; Weight Gain

Summary: the primary purpose of this study is to assess the responses of pregnant women and their social network to six videos about health in pregnancy. our goal is to assess a) acceptability and b) understanding of core messages about healthy eating, exercise and weight gain during pregnancy. we will also assess c) non-clinical sources of health information during pregnancy.

many women engage in suboptimal lifestyle behaviors during pregnancy. many women do not realize that unhealthy diet, exercise and weight gain behaviors can be dangerous for their pregnancy and have harmful long-term consequences for their baby. there is great need for strategies to promote accurate knowledge about healthy behaviors during pregnancy. the purpose of this study is to assess responses to a brief (\<1minute) video about healthy behaviors during pregnancy. the study sample will include pregnant women and members of their social network. participants will be asked to watch a brief video and complete an anonymous online survey measuring their response to the video, and their basic demographics. the surveys will also assess how family and friends impact pregnant women's health behaviors. online surveys are entirely anonymous. we will recruit pregnant participants from two sources: the university of michigan health system's prenatal clinics and a social media website (facebook).

Eligibility criteria:
inclusion criteria: * women * currently pregnant * age 18 or over * english-speaking exclusion criteria: * deny being currently pregnant * do not identify as living in the us and aged 18 years or older * report having previously participated in the study

Keywords: video messaging exercise diet weight gain pregnancy